Cancer Database Query Results

CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
7708- ,  lpi,    Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
- Trial, CRC, NA
PFS↑,
5278- 3BP,    The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression
- in-vitro, CRC, HCT116 - in-vitro, CRC, Caco-2 - in-vitro, CRC, SW48
ATP↓, TumCD↑, selectivity↑, toxicity↓, OS↑, HK2?, Cyt‑c↑, eff↑, p‑Akt↑,
5263- 3BP,  CET,    3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis
- in-vitro, CRC, DLD1 - NA, NA, HCT116
eff↑, Ferroptosis↓, TumAuto↑, Apoptosis↑, FOXO3↑, AMPKα↑, p‑Beclin-1/ATG6↑, HK2↓, ATP↓, ROS↑, Dose↝, TumVol↓, TumW↓, xCT/SLC7A11↑, GSH↓, eff↓, MDA↑,
4774- 5-FU,  TQ,  CoQ10,    Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation
- in-vitro, CRC, NA
AntiCan↑, TumCCA↑, Apoptosis↑, eff↑, Bcl-2↓, survivin↓, P21↑, p27/CDKN1B↑, BAX↑, Cyt‑c↑, Casp3↑, PI3K↓, Akt↓, mTOR↓, Hif1a↓, PTEN↑, AMPKα↑, PDH↑, LDHA↓, antiOx↓, ROS↑, AntiCan↑,
5469- AF,    Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation
- in-vitro, CRC, HCT116
eff↑, Half-Life↑,
944- AG,    Astragalus saponins inhibit cell growth, aerobic glycolysis and attenuate the inflammatory response in a DSS-induced colitis model
- vitro+vivo, CRC, NA
Glycolysis↓, lactateProd↓, TumCG↓,
5428- AG,    Meta-Analysis of Astragalus-Containing Traditional Chinese Medicine Combined With Chemotherapy for Colorectal Cancer: Efficacy and Safety to Tumor Response
- Review, CRC, NA
ChemoSen↑, chemoP↑, QoL↑, RenoP∅, hepatoP∅,
4403- AgNPs,    Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vitro, GBM, GL26 - in-vitro, Cerv, HeLa - in-vitro, CRC, RKO
AntiCan↑, eff↑, EPR↑, selectivity↑, ROS↑, Casp↑, Apoptosis↑, DNAdam↑, tumCV↓, eff↑,
4412- AgNPs,    Biosynthesis and characterization of silver nanoparticles from Asplenium dalhousiae and their potential biological properties
- in-vitro, CRC, HCT116 - in-vitro, Melanoma, A2780S
Bacteria↓, antiOx↑, AntiCan↑, eff↑,
4362- AgNPs,    Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vivo, NA, NA
eff↑, TumCG↓, OS↑, RadioS↑, eff↑, ROS↑, DNAdam↑, eff↝,
4379- AgNPs,    Exposure to silver nanoparticles induces size- and dose-dependent oxidative stress and cytotoxicity in human colon carcinoma cells
- in-vitro, CRC, LoVo
eff↑, TumCD↑, ROS↑, Bacteria↓,
4561- AgNPs,  VitC,    Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts
- in-vitro, CRC, HCT116 - in-vitro, Nor, HEK293
NRF2↑, TumCCA↑, ROS↑, selectivity↑, *AntiViral↑, *toxicity↝, ETC↓, MMP↓, DNAdam↑, Apoptosis↑, lipid-P↑, other↝, UPR↑, *GRP78/BiP↑, *p‑PERK↑, *cl‑eIF2α↑, *CHOP/DDIT3↑, *JNK↑, Hif1a↓, AntiCan↑, *toxicity↓, eff↑,
4559- AgNPs,    Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation
- in-vitro, BC, SkBr3 - in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, Colon, Caco-2
MMP2↓, MMP9↓, ROS↑, TumAuto↑, Apoptosis↑, ER Stress↑,
4557- AgNPs,    The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells
- in-vitro, NA, NIH-3T3 - in-vitro, CRC, HCT116
Cyt‑c↑, ROS↑, JNK↑,
5143- AgNPs,    Thermal Co-reduction engineered silver nanoparticles induce oxidative cell damage in human colon cancer cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis
- in-vitro, CRC, HCT116
ROS↑, lipid-P↑, GSH↓, MMP↓, Casp3↑, Apoptosis↑, TumCCA↑,
5142- AgNPs,    Biosynthesized Protein-Capped Silver Nanoparticles Induce ROS-Dependent Proapoptotic Signals and Prosurvival Autophagy in Cancer Cells
- in-vitro, CRC, HUH7
ROS↑, Apoptosis↑, eff↑, ChemoSen↑, EPR↑, Casp↑, MAPK↑,
340- AgNPs,    Screening bioactivities of Caesalpinia pulcherrima L. swartz and cytotoxicity of extract synthesized silver nanoparticles on HCT116 cell line
- in-vitro, CRC, HCT116
TumCD↑,
364- AgNPs,    Differential Action of Silver Nanoparticles on ABCB1 (MDR1) and ABCC1 (MRP1) Activity in Mammalian Cell Lines
- in-vitro, Lung, A549 - in-vitro, Hepat, HepG2 - in-vitro, CRC, SW-620
TumCD↑,
399- AgNPs,  SIL,    Cytotoxic potentials of silibinin assisted silver nanoparticles on human colorectal HT-29 cancer cells
- in-vitro, CRC, HT-29
P53↑,
5167- AL,    The Effects of Allicin, a Reactive Sulfur Species from Garlic, on a Selection of Mammalian Cell Lines
- in-vitro, Nor, 3T3 - in-vitro, BC, MCF7 - in-vitro, Lung, A549 - in-vitro, CRC, HT-29
Thiols↓, tumCV↓, TumCP↓, GSH↓, GSSG↑, ROS↑,
2668- AL,  Rad,    Allicin enhances the radiosensitivity of colorectal cancer cells via inhibition of NF-κB signaling pathway
- in-vitro, CRC, HCT116
RadioS↑, NF-kB↓,
1351- And,  MEL,    Impact of Andrographolide and Melatonin Combinatorial Drug Therapy on Metastatic Colon Cancer Cells and Organoids
- in-vitro, CRC, T84 - in-vitro, CRC, COLO205 - in-vitro, CRC, HT-29 - in-vitro, CRC, DLD1
eff↑, Ki-67↓, Casp3↑, ER Stress↑, ROS↑, BAX↑, XBP-1↑, CHOP/DDIT3↑, eff↑,
1294- And,  5-FU,    Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression
- in-vitro, CRC, HCT116
Apoptosis↑, BAX↑,
1009- And,  5-FU,    Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer
- in-vivo, CRC, HCT116 - in-vitro, CRC, SW480
ChemoSen↑, Casp9↑, Ferroptosis↑, Wnt/(β-catenin)↓, FTL↑, TP53↑, ACSL5↑, GCLC↑, GCLM↑, SAT1↑, STEAP3↑, ACSL5↑,
1008- Api,    Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW480
Wnt/(β-catenin)↓, β-catenin/ZEB1↓, TumAuto↑, Akt↓, mTOR↓, tumCV↓, TumCCA↑, TumAuto↑, p‑Akt↓, p‑p70S6↓, p‑4E-BP1↓,
578- Api,  Cisplatin,    Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis
- in-vitro, Lung, A549 - in-vitro, BC, MCF7 - in-vitro, CRC, HCT116 - in-vitro, Pca, HeLa - in-vitro, Lung, H1299
p‑P53↑,
206- Api,    Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress
- in-vitro, Lung, H1299 - in-vitro, Lung, H460 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, Melanoma, A375 - in-vitro, Lung, H2030 - in-vitro, CRC, SW480
Glycolysis↓, lactateProd↓, PGK1↓, ALDOA↓, GLUT1↓, ENO1↓, ATP↓, Casp9↑, Casp3↑, cl‑PARP↑, PI3K/Akt↓, HK1↓, HK2↓, ROS↑, Apoptosis↑, eff↓, NADPH↓, PPP↓,
175- Api,    Apigenin up-regulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT
- vitro+vivo, CRC, SW480 - vitro+vivo, CRC, DLD1 - vitro+vivo, CRC, LS174T
MMP↓, p‑Akt↓, TumCP↓, TumCI↓, NADH↓, HSP90↓, other↑, talin?,
172- Api,    Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway
- in-vitro, CRC, SW480 - in-vitro, CRC, HTC15
Wnt/(β-catenin)↓, TCF↓, LEF1↓, TumCP↓, TumCMig↓, TumCI↓,
174- Api,    Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells
- in-vitro, CRC, SW480 - in-vitro, CRC, DLD1
NEDD9↓, TumCMig↓, TumCI↓,
2634- Api,    Apigenin induces both intrinsic and extrinsic pathways of apoptosis in human colon carcinoma HCT-116 cells
- in-vitro, CRC, HCT116
TumCG↓, TumCCA↑, MMP↓, ROS↑, Ca+2↑, ER Stress↑, mtDam↑, CHOP/DDIT3↑, DR5↑, cl‑BID↑, BAX↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, Apoptosis↑,
2316- Api,    The interaction between apigenin and PKM2 restrains progression of colorectal cancer
- in-vitro, CRC, LS174T - in-vitro, CRC, HCT8 - in-vivo, CRC, NA
TumCP↓, PKM2↓, Glycolysis↓, TumCG↑, selectivity↑,
1552- Api,    Apigenin inhibits the growth of colorectal cancer through down-regulation of E2F1/3 by miRNA-215-5p
- in-vitro, CRC, HCT116
Apoptosis↑, TumCP↓, miR-215-5p↑, TumCCA↑, E2Fs↓,
5381- ART/DHA,    Artemisitene triggers calcium-dependent ferroptosis by disrupting the LSH-EWSR1 interaction in colorectal cancer
- in-vitro, CRC, HCT116 - in-vitro, Nor, NCM460 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT8
Ferroptosis↑, CYP24A1↓, Ca+2↑, SCD1↓, FAO↑, lipid-P↑, eff↑, selectivity↑, other?,
5376- ART/DHA,    Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, SW48 - in-vitro, BC, MDA-MB-453
Ferroptosis↑, Ferritin↓, Iron↑, eff↑, TumAuto↑, LC3II↑, ROS↑,
563- ART/DHA,    Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10
- in-vitro, Colon, colon26 - in-vitro, CRC, RKO
TGF-β↓, IL10↓,
2573- ART/DHA,    Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells
- in-vitro, CRC, HCT116
eff↑,
2582- ART/DHA,  5-ALA,    Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity
- in-vivo, CRC, HCT116 - in-vitro, CRC, HCT116
eff↑, ROS↑, selectivity↑, TumCG↓, toxicity↓,
5403- ASA,    Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
- Trial, CRC, NA
Risk↓, other↝,
5410- ASA,    Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
- Study, CRC, NA
Risk↓, Dose↝, Risk↓,
5404- ASA,    Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway
- Study, CRC, NA
Risk↓, other↝, Dose↝, Risk↓, other↓, other↝, KRAS↓, other↓, other↓,
5406- ASA,    Adjuvant aspirin therapy and colorectal cancer survival
- Trial, CRC, NA
Dose↝, OS∅,
5407- ASA,    Low-dose aspirin reduces the risk of colorectal cancer recurrence in patients with resected PI3K-altered localised disease, according to the ALASCCA trial.
- Trial, CRC, NA
Dose↝, Risk↓,
1304- ASA,    Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells
- in-vitro, CRC, NA - in-vivo, NA, NA
TumCP↓, Apoptosis↑, Bcl-2↓, BAX↑, IL10↓, LTA/TNF-β↓,
5398- Ash,    Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, TumCMig↓, TumCI↓, HSP90↓, Hif1a↓, EMT↓,
1356- Ash,    Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells
- in-vitro, CRC, HCT116
ROS↑, TumCCA↑, MMP↓, TumCG↓, Apoptosis↑, JNK↝,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP/DDIT3↑, p‑eIF2α↑, ICD↑, eff↑,
1179- Ash,    Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCP↓, TumCMig↓, STAT3↓, TumVol↓, TumW↓,
4812- ASTX,    Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a
- in-vitro, CRC, HCT116
miR-29b↑, miR-200b↑, MMP2↓, Zeb1↓, EMT↓, Apoptosis↑, ERK↓, MAPK↓, PI3K↓, Akt↓, MMPs↓, TumMeta↓,
4806- ASTX,    Astaxanthin's Impact on Colorectal Cancer: Examining Apoptosis, Antioxidant Enzymes, and Gene Expression
- in-vitro, CRC, HCT116
BAX↑, Casp3↑, Apoptosis↑, Bcl-2↓, MDA↓, ROS↓, SOD↑, Catalase↑, GPx↑, antiOx↑, TumCG↓, TumCP↓,

Showing Research Papers: 1 to 50 of 461
Page 1 of 10 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 461

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

8-oxo-dG↑, 1,   ABCC2↓, 1,   AEs∅, 1,   APG↓, 2,   Buty↑, 2,   CASP4↑, 1,   CBS↑, 1,   ChrCon↑, 1,   DCR↑, 1,   FGFR4/CD334↓, 1,   HSP60/HSPD1↓, 3,   HTRA↓, 2,   IL13↓, 1,   LIFR/CD118↓, 1,   miR-106b↓, 1,   miR-149↑, 1,   miR-195↑, 1,   miR-490↑, 1,   Mucositis↓, 1,   NHEJ↓, 1,   OGFr↑, 1,   ORR∅, 1,   PA↑, 1,   PC↑, 1,   PFS↑, 1,   PFS∅, 1,   PSEN2/PS-2↓, 1,   RBC↑, 1,   SCFAs↑, 3,   SUV39H↓, 1,   TCF7/TCF1↓, 1,   TF-Ag↓, 1,   WBC↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 6,   Catalase↓, 1,   Catalase↑, 4,   ENOX2↓, 1,   ENOX2↑, 1,   Fenton↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 11,   GCLC↑, 1,   GCLM↑, 1,   GPx↑, 2,   GPx1↓, 1,   GPx4↓, 5,   GSH↓, 15,   GSH↑, 2,   GSH/GSSG↓, 1,   GSS↑, 1,   GSSG↑, 1,   GSTP1/GSTπ↓, 1,   GSTs↓, 1,   GSTs↝, 1,   H2O2↑, 1,   i-H2O2↑, 1,   HK1↓, 1,   HO-1↓, 3,   HO-1↑, 4,   ICD↑, 2,   Iron↓, 1,   Iron↑, 5,   lipid-P↓, 1,   lipid-P↑, 7,   MDA↓, 2,   MDA↑, 3,   NADH↓, 1,   NQO1↓, 1,   NRF2↓, 10,   NRF2↑, 8,   OXPHOS↓, 1,   OXPHOS↑, 2,   PARK2↑, 1,   Prx↓, 1,   Prx6↑, 1,   ROS↓, 16,   ROS↑, 101,   ROS⇅, 4,   ROS↝, 1,   ROS∅, 1,   i-ROS↑, 1,   mt-ROS↓, 1,   mt-ROS↑, 6,   selenoP↓, 1,   SIRT3↑, 1,   SOD↓, 2,   SOD↑, 3,   SOD1↓, 1,   Thiols↓, 2,   TKT↓, 2,   Trx↓, 1,   Trx1↑, 1,   TrxR↓, 3,   TrxR1?, 1,   TrxR1↓, 1,   TrxR1↑, 1,   xCT/SLC7A11↓, 2,   xCT/SLC7A11↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   FTH1↓, 1,   FTL↑, 1,   IronCh↑, 1,   selm↑, 1,   STEAP3↓, 1,   STEAP3↑, 1,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1,   AIF↑, 2,   ATP↓, 10,   ATP↑, 1,   ATP⇅, 1,   i-ATP↓, 1,   CDC2↓, 1,   CDC25↓, 2,   ETC↓, 2,   MEK↓, 1,   p‑MEK↓, 1,   mitResp↓, 2,   mitResp↑, 2,   MMP↓, 50,   MMP↑, 2,   MPT↑, 1,   mtDam↑, 11,   OCR↓, 1,   OCR↑, 1,   PGC-1α↑, 1,   PINK1↑, 1,   p‑Raf↓, 1,   XIAP↓, 9,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   ACC↑, 1,   p‑ACC-α↑, 1,   ACSL1↓, 1,   ACSL5↑, 2,   AKT1↓, 4,   ALAT↓, 1,   ALAT↑, 1,   ALDOA↓, 2,   AMPK↑, 7,   AMPK↝, 1,   p‑AMPK↑, 3,   BUN↓, 1,   cMyc↓, 11,   CPT1A↓, 1,   CREB↓, 1,   ECAR↓, 2,   ENO1↓, 2,   ERCC1↓, 1,   FAO↓, 1,   FAO↑, 1,   FASN↓, 3,   FDG↓, 1,   GAPDH↓, 1,   glucose↓, 1,   glucose↑, 1,   GlucoseCon↓, 6,   Glycolysis↓, 21,   HK2?, 1,   HK2↓, 8,   HMG-CoA↓, 1,   IDO1↓, 1,   IR↓, 1,   lactateProd↓, 13,   LDH↓, 1,   LDH↑, 2,   LDHA↓, 6,   lipoGen↓, 1,   NAD↓, 1,   NAD↑, 1,   NADH:NAD↓, 1,   NADPH↓, 2,   NNMT↓, 1,   PDH↑, 2,   PDK1 / PDPK1↓, 2,   PDKs↓, 3,   PFK1↓, 1,   PGK1↓, 1,   PI3K/Akt↓, 2,   PKM2↓, 15,   PKM2↑, 1,   PPARα↝, 1,   PPARγ↑, 2,   PPP↓, 3,   Pyruv↓, 1,   p‑S6↓, 1,   S6K↓, 1,   p‑S6K↓, 1,   SAT1↑, 1,   SCD1↓, 1,   SIRT1↓, 2,   TS↓, 2,   Warburg↓, 9,  

Cell Death(tgid=5) ⓘ

AhR↑, 1,   Akt↓, 36,   Akt↑, 3,   Akt∅, 1,   p‑Akt↓, 18,   p‑Akt↑, 1,   APAF1↑, 2,   Apoptosis↓, 4,   Apoptosis↑, 150,   mt-Apoptosis↑, 2,   p‑ASK1↑, 1,   ATF2↓, 1,   BAD↑, 4,   p‑BAD↓, 1,   Bak↑, 3,   BAX↑, 58,   Bax:Bcl2↑, 11,   Bcl-2↓, 76,   Bcl-2↑, 1,   Bcl-xL↓, 16,   BID↑, 2,   cl‑BID↑, 1,   BIM↑, 1,   Casp↑, 12,   Casp1↑, 2,   cl‑Casp1↑, 1,   Casp12↝, 1,   Casp3↑, 69,   cl‑Casp3↑, 15,   Casp6↑, 1,   Casp7↑, 12,   cl‑Casp7↑, 1,   Casp8↑, 16,   cl‑Casp8↑, 1,   Casp9↑, 47,   p‑Casp9↑, 1,   cl‑Casp9↑, 3,   cFLIP↓, 3,   Cyt‑c↓, 1,   Cyt‑c↑, 32,   DR4↑, 1,   DR5↑, 5,   Fas↑, 2,   Ferroptosis↓, 1,   Ferroptosis↑, 11,   cl‑GSDMD↑, 1,   cl‑GSDME↑, 1,   Hippo↓, 1,   IAP1↓, 2,   iNOS↓, 4,   JNK↓, 2,   JNK↑, 7,   JNK↝, 1,   p‑JNK↑, 2,   MAPK↓, 5,   MAPK↑, 6,   MAPK↝, 1,   p‑MAPK↑, 1,   Mcl-1↓, 2,   MCT1↓, 1,   MDM2↓, 4,   MEG3↑, 1,   miR-497↑, 1,   Myc↓, 1,   Necroptosis↑, 1,   necrosis↑, 3,   p27/CDKN1B↑, 5,   p38↓, 3,   p38↑, 6,   p‑p38↑, 1,   PUMA↑, 1,   PUMA↝, 1,   Pyro↑, 2,   survivin↓, 29,   Telomerase↓, 2,   TRAIL↑, 1,   TRPV1↑, 1,   TumCD↓, 1,   TumCD↑, 17,   YAP/TEAD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 3,   EF-1α↓, 1,   HCAR2↑, 2,   miR-25-5p↑, 1,   p70S6↓, 2,   p‑p70S6↓, 1,   Sp1/3/4↓, 3,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

COMP↓, 1,   EZH2↓, 1,   ac‑H3↝, 1,   HATs↑, 1,   KCNQ1OT1↓, 1,   miR-145↑, 1,   miR-21↓, 2,   miR-27a-3p↓, 2,   miR-27a-3p↑, 1,   miR-409-3p↑, 1,   other?, 2,   other↓, 6,   other↑, 4,   other↝, 14,   TET3↑, 1,   tumCV?, 2,   tumCV↓, 55,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 8,   i-CRT↓, 1,   eIF2α↓, 1,   eIF2α↑, 4,   p‑eIF2α↑, 2,   ER Stress↑, 19,   GRP78/BiP↓, 1,   GRP78/BiP↑, 5,   HSP27↓, 2,   HSP27↑, 1,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 1,   HSP70/HSPA5⇅, 1,   HSP90↓, 4,   IRE1↓, 1,   IRE1↑, 1,   PERK↑, 4,   UPR↑, 3,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 2,   Beclin-1/ATG6↑, 5,   Beclin-1/ATG6⇅, 1,   p‑Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3B↑, 2,   LC3II↑, 3,   LC3s↑, 1,   p62↓, 2,   p62↑, 3,   SESN2↑, 1,   TumAuto↓, 1,   TumAuto↑, 18,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   DNAdam↓, 3,   DNAdam↑, 22,   DNMT1↓, 3,   DNMT3A↓, 2,   DNMTs↓, 2,   NBR2↑, 1,   p16↑, 1,   P53?, 1,   P53↓, 2,   P53↑, 28,   p‑P53↑, 2,   ac‑P53↑, 1,   i-P53↓, 1,   PARP↓, 5,   PARP↑, 7,   p‑PARP↑, 1,   cl‑PARP↑, 30,   PARP1↓, 1,   cl‑PARP1↑, 2,   PCNA↓, 2,   TP53↑, 1,   γH2AX↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK1↑, 1,   CDK2↓, 4,   CDK2↑, 1,   CDK4↓, 8,   CDK4↑, 1,   cycA1/CCNA1↓, 1,   cycA1/CCNA1↑, 2,   CycB/CCNB1↓, 2,   CycB/CCNB1↑, 2,   cycD1/CCND1↓, 35,   cycD1/CCND1↑, 2,   CycD3↓, 1,   cycE/CCNE↓, 5,   cycE/CCNE↑, 1,   E2Fs↓, 2,   mitA↑, 1,   P21↓, 2,   P21↑, 22,   p‑RB1↓, 3,   TFAP2A↓, 1,   TumCCA↓, 4,   TumCCA↑, 88,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   p‑4E-BP1↓, 1,   ALDH↓, 1,   ALDH1A1↓, 1,   AXIN1↓, 1,   BMI1↓, 2,   CD133↓, 4,   CD24↓, 1,   CD44↓, 5,   cDC2↓, 1,   CDK8↓, 1,   CDX2↓, 1,   CEBPB?, 1,   cFos↓, 1,   cMYB↓, 1,   CSCs↓, 17,   CSCs↑, 1,   CSCsMark↓, 1,   CTNNB1↓, 1,   Diff↓, 1,   Diff↑, 1,   EMT↓, 24,   EMT↑, 1,   EP2↓, 1,   EP4/PTGER4↓, 1,   ERK↓, 9,   ERK↑, 2,   ERK∅, 1,   p‑ERK↓, 2,   p‑ERK↑, 1,   FOXO1↑, 1,   FOXO3↓, 2,   FOXO3↑, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 2,   HDAC↓, 14,   HDAC4↓, 1,   HH↓, 4,   IGF-1↓, 2,   IGFR↓, 1,   Let-7↑, 2,   LGR5↓, 2,   miR-34a↑, 6,   mTOR↓, 21,   mTOR↑, 2,   mTOR↝, 1,   p‑mTOR↓, 3,   Nanog↓, 2,   NKD2↑, 2,   NOTCH↓, 2,   NOTCH1↓, 1,   NOTCH1↝, 1,   p300↓, 1,   P70S6K↓, 1,   PDGFRA↓, 1,   PI3K↓, 25,   PI3K↝, 1,   p‑PI3K↓, 7,   PTEN↑, 5,   RAS?, 1,   Shh↓, 1,   Src↓, 1,   STAT↓, 3,   p‑STAT↓, 1,   STAT3↓, 19,   p‑STAT3↓, 7,   i-STAT3↓, 1,   STAT4↑, 1,   SUZ12↓, 1,   TCF↓, 4,   TK1↓, 1,   TOPflash↓, 2,   TOPflash↑, 1,   TumCG?, 1,   TumCG↓, 91,   TumCG↑, 1,   VDR↑, 1,   Wnt↓, 11,   Wnt↝, 1,   Wnt/(β-catenin)↓, 5,  

Migration(tgid=13) ⓘ

5LO↓, 2,   AGRN↓, 1,   AP-1↓, 3,   AP-1↝, 1,   Ca+2↑, 10,   Ca+2↝, 1,   i-Ca+2↑, 1,   mt-Ca+2↑, 1,   cal2↑, 1,   CC(CDKs/cyclins)↓, 1,   CCN2/CTGF↓, 1,   CD31/PECAM-1↓, 1,   COL2A1↓, 1,   COL9A3↓, 1,   E-cadherin↓, 4,   E-cadherin↑, 17,   FAK↓, 2,   p‑FAK↓, 2,   FTO↑, 1,   GP1BB↓, 1,   ITGB1↓, 1,   ITGB4↓, 1,   ITGB6↓, 1,   Ki-67↓, 12,   Ki-67↑, 1,   KRAS↓, 3,   LAMA5↓, 1,   LEF1↓, 1,   MALAT1↓, 1,   MET↑, 2,   miR-130a↓, 1,   miR-139-5p↑, 1,   miR-155↓, 2,   miR-200b↑, 2,   miR-200c↑, 1,   miR-215-5p↑, 1,   miR-221↓, 1,   miR-29b↑, 1,   MMP2↓, 14,   MMP7↓, 2,   MMP9↓, 20,   MMPs↓, 7,   N-cadherin↓, 12,   NEDD9↓, 1,   p‑pax↓, 1,   Rho↓, 1,   Slug↓, 4,   Smad1↓, 1,   SMAD2↓, 1,   p‑SMAD2↓, 1,   SMAD3↓, 1,   p‑SMAD3↓, 1,   SMAD4↑, 1,   Snail↓, 8,   talin?, 1,   TET1↑, 3,   TGF-β↓, 5,   TGF-β1↓, 1,   TIMP2↑, 1,   Treg lymp↓, 1,   TumCA↓, 1,   TumCI?, 1,   TumCI↓, 36,   TumCMig↓, 49,   TumCMig↑, 1,   TumCP↓, 101,   TumCP↑, 5,   TumCP⇅, 1,   TumCP∅, 1,   TumMeta↓, 18,   TumMeta↑, 1,   TumPF↓, 1,   Twist↓, 4,   Twist↑, 1,   TXNIP↑, 1,   uPA↓, 1,   UroPA↓, 1,   VEGFR1↓, 1,   Vim↓, 10,   Vim↑, 2,   Zeb1↓, 4,   ZEB2↓, 1,   ZO-1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 28,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 11,   angioG↑, 2,   ATF4↑, 3,   ECM/TCF↓, 2,   EGFR↓, 8,   Endoglin↑, 1,   EPR↑, 3,   HIF-1↓, 1,   Hif1a↓, 17,   Hif1a↝, 1,   miR-17↓, 1,   PDI↑, 1,   VEGF↓, 17,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

AQPs↓, 2,   GLUT1↓, 7,   IBI↑, 2,   MRP↓, 2,   P-gp/ABCB1↓, 1,   SLC12A5↝, 1,   SMCT1↑, 1,   SMCT1∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 2,   cellSen↑, 1,   COX1↓, 1,   COX2/PTGS2↓, 18,   COX2/PTGS2↑, 1,   CXCR4↓, 4,   DCells↑, 1,   FOXP3↓, 1,   Gal1↑, 1,   HCAR2↑, 2,   HMGB1↓, 4,   i-HMGB1↓, 1,   ICAM-1↓, 2,   IFN-γ↓, 1,   IFN-γ↑, 3,   IKKα↓, 3,   IKKα↑, 1,   p‑IKKα↓, 1,   IL10↓, 3,   IL10↑, 1,   IL12↑, 1,   IL18↑, 1,   IL1β↓, 6,   IL2↓, 1,   IL4↓, 3,   IL4↑, 1,   IL6↓, 16,   IL6↑, 1,   IL8↓, 6,   Imm↑, 4,   Imm↝, 2,   INF-γ↝, 1,   Inflam↓, 19,   Inflam↑, 2,   JAK↓, 1,   JAK1?, 1,   p‑JAK1↓, 1,   JAK2↓, 1,   p‑JAK2↓, 2,   LTA/TNF-β↓, 1,   MCP1/CCL2↓, 1,   MIP2↓, 1,   mPGES-1↓, 1,   Neut↑, 2,   NF-kB↓, 34,   NF-kB↑, 1,   p‑NF-kB↓, 1,   p‑NF-kB↑, 2,   NK cell↑, 2,   p50↓, 1,   p65↓, 2,   p‑p65↓, 2,   PD-L1↓, 4,   PD-L1↑, 1,   PGE2↓, 4,   T-Cell↑, 3,   Th1 response?, 1,   TLR1↑, 2,   TLR2↑, 1,   TLR4↓, 3,   TLR4↑, 1,   TNF-α↓, 11,   TNF-α↑, 2,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,   pH↓, 1,   e-pH↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

ChE↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 2,   CYP11A1↓, 1,   CYP24A1↓, 1,   ERβ/ESR2↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 6,   BioAv↝, 4,   BioEnh↑, 2,   ChemoSen↓, 2,   ChemoSen↑, 50,   ChemoSen⇅, 1,   ChemoSen↝, 1,   ChemoSen∅, 1,   DDS↑, 1,   Dose?, 1,   Dose↓, 3,   Dose↑, 3,   Dose↝, 50,   Dose∅, 3,   eff↓, 39,   eff↑, 77,   eff⇅, 1,   eff↝, 8,   eff∅, 2,   Half-Life↑, 3,   Half-Life↝, 2,   P450↝, 1,   RadioS↑, 14,   selectivity↓, 1,   selectivity↑, 53,   TET2↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALAT↑, 1,   Albumin↑, 1,   ALP↑, 1,   ascitic↓, 1,   AST↓, 1,   AST↑, 1,   creat↓, 1,   EGFR↓, 8,   EZH2↓, 1,   Ferritin↓, 1,   GutMicro↓, 1,   GutMicro↑, 11,   GutMicro↝, 1,   Hcy/homoC↓, 1,   IL6↓, 16,   IL6↑, 1,   Ki-67↓, 12,   Ki-67↑, 1,   KRAS↓, 3,   LDH↓, 1,   LDH↑, 2,   Myc↓, 1,   PD-L1↓, 4,   PD-L1↑, 1,   SUZ12↓, 1,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 33,   AntiTum↑, 13,   Appetite↑, 1,   chemoP↑, 7,   chemoPv↑, 11,   cognitive↑, 1,   fatigue↓, 2,   hepatoP∅, 1,   OS↑, 16,   OS∅, 2,   Pain↓, 1,   Pin1↓, 1,   QoL↑, 4,   QoL∅, 1,   radioP↑, 1,   RenoP∅, 1,   Risk↓, 33,   Risk↑, 1,   Risk↝, 1,   Risk∅, 1,   Sleep↑, 1,   Symptoms∅, 1,   toxicity↓, 7,   toxicity↝, 1,   TumVol↓, 22,   TumVol↑, 1,   TumVol⇅, 1,   TumW↓, 8,   TumW⇅, 1,   Weight∅, 2,   Wound Healing↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 2,   CD8+↑, 6,   Diar↓, 1,   Inf↓, 4,  
Total Targets: 727

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 3,   TPH1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 3,   antiOx↑, 15,   Catalase↑, 4,   GPx↑, 3,   GSH↓, 1,   GSH↑, 1,   GSTA1↑, 1,   HO-1↑, 3,   lipid-P↓, 3,   MDA↓, 2,   NQO1↑, 1,   NRF2↑, 7,   Prx↑, 1,   ROS↓, 10,   ROS∅, 1,   SOD↑, 4,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ECAR∅, 1,  

Cell Death(tgid=5) ⓘ

Akt↝, 1,   Apoptosis↓, 1,   Casp1↓, 1,   iNOS↓, 1,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↓, 1,   MAPK↝, 1,   p‑p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 2,   other?, 1,   other↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   cl‑eIF2α↑, 1,   GRP78/BiP↑, 1,   p‑PERK↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNArepair↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↝, 1,   ERK↓, 1,   p‑ERK↑, 1,   PI3K↓, 1,   STAT3↝, 1,   TumCG∅, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   AP-1↓, 1,   MMP13↓, 1,   TGF-β↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2/PTGS2↓, 2,   IL1β↓, 1,   IL4↓, 1,   IL6↓, 2,   Inflam↓, 19,   NF-kB↓, 1,   PGE2↓, 2,   TNF-α↓, 2,   VitD↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioAv↝, 1,   eff↓, 1,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 3,   IL6↓, 2,   VitD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   AntiP↓, 1,   cardioP↑, 5,   chemoP↑, 2,   hepatoP↑, 3,   memory↑, 1,   neuroP↑, 6,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 11,   toxicity↝, 2,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 3,   Bacteria↓, 1,  
Total Targets: 86

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page